» Articles » PMID: 1131654

Cellular Immunity in Cancer: Comparison of Delayed Hypersensitivity Skin Tests in Three Common Cancers

Overview
Journal Br Med J
Specialty General Medicine
Date 1975 Jul 5
PMID 1131654
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Cellular immunity was studied in three homogenous groups of patients with cancer to determine whether the pattern of depression of immune competence varied between solid tumours with different patterns of clinical behaviour. Delayed hypersensitivity skin responses were measured in patients with carcinoma of the breast, stomach, and colon and matched controls. Response to 2,4-dinitrochlorobenzene (DNCB) was used as an indication of primary responses and the Mantoux reaction as an index of recall responses. Responses were diminished in all three cancer groups, but there were significant differences between each type of cancer and even between different control groups. Cellular immunity was lost earliest and to the greatest extent in patients with colonic cancers and tended to be retained until a late stage in breast cancer, with gastric cancer occupying an intermediate position. Thus, while there was some degree of correlation between depressed immunity and prognosis our results gave no evidence that general host immune competence could explain the worse prognosis of gastric than colonic cancer. Paradoxical findings in patients with breast cancer suggested a great complexity in the host tumour interaction. Assessments of immune competence in cancer patients must be related to specific types of neoplasms with appropriate control groups if the results are to be meaningful.

Citing Articles

Impaired cytokine production in whole blood cell cultures of patients with gynaecological carcinomas in different clinical stages.

Elsasser-Beile U, von Kleist S, Sauther W, Gallati H, Monting J Br J Cancer. 1993; 68(1):32-6.

PMID: 8318418 PMC: 1968320. DOI: 10.1038/bjc.1993.282.


Dissociation between tumour resistance and delayed-type hypersensitivity to tumour-associated antigens in the mouse.

Henderson D, Parker D, Turk J Immunology. 1980; 39(1):1-9.

PMID: 7380461 PMC: 1457770.


Nutrition in the cancer patient: a review.

Dickerson J J R Soc Med. 1984; 77(4):309-15.

PMID: 6425499 PMC: 1439740. DOI: 10.1177/014107688407700411.


Serial immune function testing to predict clinical disease relapse in patients with solid tumors.

Braun D, Harris J Cancer Immunol Immunother. 1983; 15(3):165-71.

PMID: 6352007 PMC: 11039147. DOI: 10.1007/BF00199159.


Adjuvant treatment of colorectal cancer. Current status and concepts.

Metzger U, Ghosh B, Kisner D Cancer Chemother Pharmacol. 1985; 14(1):1-8.

PMID: 3880669 DOI: 10.1007/BF00552715.


References
1.
Aisenberg A . Studies on delayed hypersensitivity in Hodgkin's disease. J Clin Invest. 1962; 41:1964-70. PMC: 291126. DOI: 10.1172/JCI104654. View

2.
Bone G, LAUDER I . Cellular immunity, peripheral blood lymphocyte count and pathological staging of tumours in the gastrointestinal tract. Br J Cancer. 1974; 30(3):215-21. PMC: 2009205. DOI: 10.1038/bjc.1974.184. View

3.
Khoo S, Mackay E . Relation of cell-mediated immunity in women with genital tract cancer to origin, histology, clinical stage and subsequent behaviour of neoplasm. J Obstet Gynaecol Br Commonw. 1974; 81(3):229-35. DOI: 10.1111/j.1471-0528.1974.tb00450.x. View

4.
Eilber F, Morton D . Impaired immunologic reactivity and recurrence following cancer surgery. Cancer. 1970; 25(2):362-7. DOI: 10.1002/1097-0142(197002)25:2<362::aid-cncr2820250213>3.0.co;2-v. View

5.
Nelson H . Delayed hypersensitivity in cancer patients: cutaneous and in vitro lymphocyte response to specific antigens. J Natl Cancer Inst. 1969; 42(5):765-70. View